IL17A and neoplasm: Anti-PD-1 combined with endostar reduced MDSCs accumulation and reversed CD8 + T cell suppression through decreasing pro-inflammatory cytokine IL-17 and immunosuppressive factor TGF-β1 levels, which dramatically suppressed tumor growth in Lewis lung carcinoma (LLC) mouse models (94).